PATENT CLAIM ANALYSIS

Application Number: 15920197
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["424", "139100"]

Abstract:
The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.

Claim (Index 24):
An isolated antibody, or antigen-binding fragment thereof, that binds to CD40, wherein the isolated antibody, or an antigen-binding fragment thereof, comprises (i) a heavy chain variable region comprising the VHCDR1 region set forth in SEQ ID NO:3, the VHCDR2 region set forth in SEQ ID NO:4, and the VHCDR3 region set forth SEQ ID NO:5; and (ii) a light chain variable region comprising the VLCDR1 region set forth in SEQ ID NO:6, the VLCDR2 region set forth in SEQ ID NO:7, and the VLCDR3 region set forth in SEQ ID NO: 8; and comprising an Fc region modified by a S267E mutation;\n or a variant of said antibody, or an antigen-binding fragment thereof, comprising heavy and light chain variable regions identical to the heavy and light chain variable regions of (i) and (ii) except for up to 8 amino acid substitutions in said CDR regions.

Metadata:
- Claim Count in Document: 19.0
- Percentile: 90.0
- Lexical Diversity: 1.09677
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14067770', '15594367', '14613110', '13458730', '14995741']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8075148539391376
- 35 USC 102 Novelty (BERT): 0.6012614556188308
- Combined Prediction Score: 0.786889514107107
- Mean Citation Score: 493.76353200000005
- Max Citation Score: 520.31396
- Similarity Product: 509.9655612224626

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test